StockIQ.techCencora, Inc. (COR) Stock Analysis
Free AI-powered analysis and research for Cencora, Inc. stock
Sector: Healthcare
COR snapshot
Data as of 3 Nov 2026 close. Updated daily.
Cencora, Inc. scores 25/100 on StockIQ's model, which reads as negative signals overall. The price is above its 200-day average and at 71% of its 52-week range, down 0.5% over the past year. Latest reported figures show a profit margin of 0.8%, return on equity of 96.9% and revenue growth of +5.1%.
What is driving the score
- Strong Uptrend: +12
- MACD Bearish: -8
- Weak Profit Margin (0.8%): -8
- High Debt (4.47 D/E): -10
- Low Liquidity (0.94 Current Ratio): -10
- Excellent ROE (96.9%): +8
- High P/B (20.59): -5
- Above MA200: +4
- Underperforming (-0.5% over 1 year): -5
- Low Volume (0.4x): -3
Automated, general information only – not financial advice. Scores can be wrong. How the score works
Full COR report
Cencora, Inc. (COR) is listed in the Healthcare sector. The snapshot on this page updates daily; run a full report for the complete breakdown.
Analyze COR Now →📰 Latest Update
Is Cencora (COR) Fully Valued Following Its $2.4b American Oncology Network Deal?
Sun, November 1, 2026 at 1:14 AM UTC 2 min read
Cencora (COR) has made headlines with its $2.4 billion acquisition of American Oncology Network, significantly altering its community cancer care presence. Despite a mixed market performance, with a 7.05% return over the past month and a 1.32% decline over the past year, analysts estimate the fair value of Cencora shares at about $369, compared to the recent close of $330.84, raising questions about whether the stock is fully valued following this strategic move.